

Table 3.2
Verified Outcomes (Annualized Percentages) by Race/Ethnicity for MRC Super Cohort Participants¹

Data as of: March 1, 2019; Events through March 1, 2019

Outcomes	Race/Ethnicity					
	American Indian/Alaskan Native	Asian/Pacific Islander	Black/African American	Hispanic/Latina	White	Unknown
Number randomized	130	527	14618	6484	22030	385
Mean follow-up (months)	169.0	171.4	162.8	153.8	193.9	178.0
Cardiovascular						
CHD ²	11 (0.60%)	29 (0.39%)	1010 (0.51%)	230 (0.28%)	2234 (0.63%)	33 (0.58%)
CHD death ³	7 (0.38%)	10 (0.13%)	527 (0.27%)	80 (0.10%)	921 (0.26%)	11 (0.19%)
Clinical MI	6 (0.33%)	23 (0.31%)	617 (0.31%)	176 (0.21%)	1579 (0.44%)	26 (0.46%)
Angina ⁴	7 (0.69%)	14 (0.34%)	548 (0.48%)	160 (0.33%)	884 (0.49%)	12 (0.40%)
CABG/PTCA	10 (0.55%)	23 (0.31%)	754 (0.38%)	272 (0.33%)	1927 (0.54%)	30 (0.53%)
Carotid artery disease	1 (0.05%)	4 (0.05%)	98 (0.05%)	22 (0.03%)	393 (0.11%)	3 (0.05%)
Congestive heart failure, WHI ⁴	3 (0.30%)	9 (0.22%)	477 (0.42%)	91 (0.19%)	655 (0.36%)	11 (0.37%)
Heart failure, UNC ⁵	10 (0.55%)	22 (0.29%)	801 (0.41%)	158 (0.19%)	1897 (0.54%)	23 (0.41%)
Stroke	13 (0.71%)	24 (0.32%)	873 (0.44%)	202 (0.24%)	1701 (0.48%)	26 (0.46%)
PVD	3 (0.16%)	8 (0.11%)	240 (0.12%)	27 (0.03%)	392 (0.11%)	4 (0.07%)
DVT	5 (0.27%)	4 (0.05%)	215 (0.11%)	37 (0.04%)	844 (0.24%)	6 (0.11%)
Pulmonary embolism	4 (0.22%)	2 (0.03%)	194 (0.10%)	22 (0.03%)	663 (0.19%)	11 (0.19%)
DVT/PE	8 (0.44%)	4 (0.05%)	331 (0.17%)	51 (0.06%)	1193 (0.34%)	14 (0.25%)
Coronary disease ⁶	24 (1.31%)	61 (0.81%)	2209 (1.11%)	568 (0.68%)	4533 (1.27%)	64 (1.12%)
Aortic aneurysm ⁷	0 (0.00%)	1 (0.06%)	18 (0.04%)	3 (0.02%)	40 (0.04%)	0 (0.00%)
Valvular heart disease ⁷	1 (0.25%)	3 (0.18%)	57 (0.14%)	35 (0.20%)	347 (0.39%)	5 (0.37%)
Total cardiovascular disease⁸	33 (1.80%)	88 (1.17%)	3122 (1.57%)	781 (0.94%)	6248 (1.75%)	83 (1.45%)
Cancer						
Breast cancer	8 (0.44%)	36 (0.48%)	930 (0.47%)	309 (0.37%)	1611 (0.45%)	24 (0.42%)
Invasive breast cancer	7 (0.38%)	28 (0.37%)	749 (0.38%)	252 (0.30%)	1336 (0.38%)	21 (0.37%)
In situ breast cancer	1 (0.05%)	9 (0.12%)	203 (0.10%)	63 (0.08%)	299 (0.08%)	5 (0.09%)
Ovarian cancer	1 (0.05%)	3 (0.04%)	72 (0.04%)	37 (0.04%)	155 (0.04%)	5 (0.09%)
Endometrial cancer ⁹	1 (0.13%)	2 (0.04%)	90 (0.10%)	29 (0.06%)	206 (0.09%)	2 (0.06%)
Colorectal cancer	1 (0.05%)	17 (0.23%)	291 (0.15%)	78 (0.09%)	534 (0.15%)	9 (0.16%)
Other cancer ¹⁰	13 (0.71%)	49 (0.65%)	1040 (0.52%)	347 (0.42%)	2646 (0.74%)	39 (0.68%)
Total cancer	23 (1.26%)	101 (1.34%)	2257 (1.14%)	748 (0.90%)	4764 (1.34%)	75 (1.31%)
Fractures						
Hip fracture	7 (0.38%)	11 (0.15%)	140 (0.07%)	70 (0.08%)	1291 (0.36%)	12 (0.21%)
Deaths						
Cardiovascular deaths	13 (0.71%)	19 (0.25%)	1093 (0.55%)	196 (0.24%)	2109 (0.59%)	20 (0.35%)
Cancer deaths	10 (0.55%)	38 (0.50%)	899 (0.45%)	274 (0.33%)	1816 (0.51%)	27 (0.47%)
Other known cause	14 (0.76%)	29 (0.39%)	798 (0.40%)	236 (0.28%)	2121 (0.60%)	23 (0.40%)
Unknown cause	0 (0.00%)	3 (0.04%)	28 (0.01%)	16 (0.02%)	44 (0.01%)	4 (0.07%)
Not yet adjudicated	0 (0.00%)	5 (0.07%)	78 (0.04%)	26 (0.03%)	242 (0.07%)	5 (0.09%)
Total death¹¹	50 (2.10%)	174 (1.78%)	5259 (1.98%)	1596 (1.30%)	9133 (2.24%)	137 (1.93%)

¹ The MRC Super Cohort includes all WHI Hormone Trial participants and all Black/African American and Hispanic/Latina participants from the CT and OS.

² "CHD" includes clinical MI, evolving Q-wave MI, and CHD death; Q-wave MI is not collected in the WHI Extension Studies 2005-2020.

³ "CHD death" includes definite and possible CHD death.

⁴ Angina and CHF are not verified outcomes in the WHI Extension Studies 2005-2020. Reported statistics represent experience during the original program.

⁵ Definite or possible decompensated heart failure adjudicated by UNC.

⁶ "Coronary disease" includes clinical MI, evolving Q-wave MI, possible evolving Q-wave MI, CHD death, angina, congestive heart failure, UNC heart failure, and CABG/PTCA; Q-wave MI, angina and congestive heart failure are not collected in the WHI Extension Studies 2005-2020.

⁷ Aortic aneurysm and valvular heart disease are new adjudicated outcomes during the WHI Extension Study 2010-2020.

⁸ Total CVD does not include aortic aneurysm or valvular heart disease.

⁹ Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.

¹⁰ Only one report of "other cancer" is counted per woman; however, the first of each type is adjudicated. Excludes non-melanoma skin cancer.

¹¹ Includes deaths for non-Extension study participants after the main WHI study close-out. Annualized rates incorporate additional follow-up from the NDI search.